IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Constitutive NF-κB activation is prevalent in pancreatic ductal adenocarcinoma (PDAC), driving oncogenic KRAS-induced tumor development.
• The IL-1α pathway is implicated in NF-κB activation, suggesting it as a potential therapeutic target in PDAC.

Purpose of the Study:

• To investigate if targeting the IL-1α pathway with anakinra inhibits NF-κB activity.
• To determine the efficacy of anakinra in suppressing PDAC cell growth, migration, and invasion.
• To evaluate the therapeutic potential of anakinra in combination with gemcitabine for PDAC treatment.

Main Methods:

• Assessed NF-κB activation inhibition by anakinra, an IL-1 receptor antagonist (rhIL-1R antagonist).
• Conducted cell proliferation, migration, and invasion assays using PDAC cell lines treated with rhIL-1R antagonist.
• Evaluated in vivo tumor growth in an orthotopic nude mouse model using a combination of gemcitabine and rhIL-1RA.

Main Results:

• Anakinra treatment significantly decreased NF-κB activity.
• Combined treatment with rhIL-1R antagonist and gemcitabine reduced PDAC cell proliferation, migration, and invasion compared to gemcitabine alone.
• Significant reduction in tumor burden was observed in nude mice treated with rhIL-1R antagonist and gemcitabine.

Conclusions:

• Anakinra, an FDA-approved drug, effectively inhibits IL-1α-induced NF-κB activity in PDAC.
• Combination therapy with anakinra and gemcitabine shows promise in reducing PDAC tumor growth.
• Targeting the IL-1 receptor pathway represents a viable therapeutic strategy for pancreatic ductal adenocarcinoma.